This $257,807 federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health") will support the development of living biosensors for detecting and analyzing DNA at the single-base level, without requiring sample purification or specialized equipment. The proposed biosensors will use natural bacterial competence and CRISPR-Cas systems to pull DNA from raw samples, analyze it, and produce a detectable output signal using a lateral flow assay, similar to a home pregnancy or COVID-19 test. The biosensors will be designed to detect DNA sequences associated with urinary tract pathogens, E. coli, and antibiotic-resistant Salmonella, enabling rapid and equipment-free diagnostics at the point of care. This 4-year project, running from April 2025 to March 2029, aims to develop a hybrid living biosensor/lateral flow assay that requires minimal sample preparation and expertise, yet can achieve single-base DNA resolution for a range of clinical and environmental applications.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $257.8k | 4/2/25 |